医学临床研究
醫學臨床研究
의학림상연구
JOURNAL OF CLINICAL RESEARCH
2014年
11期
2160-2162
,共3页
张骐%赵丽%夏小红%刘江
張騏%趙麗%夏小紅%劉江
장기%조려%하소홍%류강
司立吉林/治疗应用%帕金森病/并发症%睡眠障碍/病因学%睡眠障碍/药物疗法
司立吉林/治療應用%帕金森病/併髮癥%睡眠障礙/病因學%睡眠障礙/藥物療法
사립길림/치료응용%파금삼병/병발증%수면장애/병인학%수면장애/약물요법
Selegiline/TU%Parkinson Disease/CO%Sleep Disorders/ET%Sleep Disorders/DT
目的 研究司来吉兰治疗早期帕金森病(Parkinson disease ,PD)睡眠障碍的临床疗效和安全性。方法 将90例已用安坦、金刚烷胺、维生素E联合治疗的早期PD患者随机分为司来吉兰组和艾司唑仑组,前者在原用药物剂量不变的基础上添加司来吉兰片,5 mg/d ,后者添加艾司唑仑1 mg/d。疗程均为4周。90例患者在治疗前后分别进行匹兹堡睡眠质量指数(PSQI)问卷调查,分析两组患者在治疗前后的睡眠情况。同时在加药前后进行常规实验室指标检测,分析比较不良反应发生情况。结果 两组在治疗后PS Q I评分均明显好转,与治疗前相比较差异均有显著性( P <0.01)。司来吉兰组和艾司唑仑组治疗后的 PSQI评分相比较差异无显著性( P >0.05)。在PSQI中睡眠质量、日间功能、催眠药物三个因子的评分,两组在治疗后相比较差异有显著性( P<0.05)。司来吉兰组的总不良反应发生率为17.8%,艾司唑仑组为36.9%,两组间相比较差异有显著性( P <0.05) ,其中治疗后嗜睡和直立性低血压不良反应发生率比较,司来吉兰组显著低于艾司唑仑组( P <0.01)。结论 司来吉兰治疗早期帕金森病睡眠障碍安全、有效,并且在减少催眠药物的使用以及改善PD患者睡眠质量和日间功能方面明显优于艾司唑仑,值得推广应用。
目的 研究司來吉蘭治療早期帕金森病(Parkinson disease ,PD)睡眠障礙的臨床療效和安全性。方法 將90例已用安坦、金剛烷胺、維生素E聯閤治療的早期PD患者隨機分為司來吉蘭組和艾司唑崙組,前者在原用藥物劑量不變的基礎上添加司來吉蘭片,5 mg/d ,後者添加艾司唑崙1 mg/d。療程均為4週。90例患者在治療前後分彆進行匹玆堡睡眠質量指數(PSQI)問捲調查,分析兩組患者在治療前後的睡眠情況。同時在加藥前後進行常規實驗室指標檢測,分析比較不良反應髮生情況。結果 兩組在治療後PS Q I評分均明顯好轉,與治療前相比較差異均有顯著性( P <0.01)。司來吉蘭組和艾司唑崙組治療後的 PSQI評分相比較差異無顯著性( P >0.05)。在PSQI中睡眠質量、日間功能、催眠藥物三箇因子的評分,兩組在治療後相比較差異有顯著性( P<0.05)。司來吉蘭組的總不良反應髮生率為17.8%,艾司唑崙組為36.9%,兩組間相比較差異有顯著性( P <0.05) ,其中治療後嗜睡和直立性低血壓不良反應髮生率比較,司來吉蘭組顯著低于艾司唑崙組( P <0.01)。結論 司來吉蘭治療早期帕金森病睡眠障礙安全、有效,併且在減少催眠藥物的使用以及改善PD患者睡眠質量和日間功能方麵明顯優于艾司唑崙,值得推廣應用。
목적 연구사래길란치료조기파금삼병(Parkinson disease ,PD)수면장애적림상료효화안전성。방법 장90례이용안탄、금강완알、유생소E연합치료적조기PD환자수궤분위사래길란조화애사서륜조,전자재원용약물제량불변적기출상첨가사래길란편,5 mg/d ,후자첨가애사서륜1 mg/d。료정균위4주。90례환자재치료전후분별진행필자보수면질량지수(PSQI)문권조사,분석량조환자재치료전후적수면정황。동시재가약전후진행상규실험실지표검측,분석비교불량반응발생정황。결과 량조재치료후PS Q I평분균명현호전,여치료전상비교차이균유현저성( P <0.01)。사래길란조화애사서륜조치료후적 PSQI평분상비교차이무현저성( P >0.05)。재PSQI중수면질량、일간공능、최면약물삼개인자적평분,량조재치료후상비교차이유현저성( P<0.05)。사래길란조적총불량반응발생솔위17.8%,애사서륜조위36.9%,량조간상비교차이유현저성( P <0.05) ,기중치료후기수화직립성저혈압불량반응발생솔비교,사래길란조현저저우애사서륜조( P <0.01)。결론 사래길란치료조기파금삼병수면장애안전、유효,병차재감소최면약물적사용이급개선PD환자수면질량화일간공능방면명현우우애사서륜,치득추엄응용。
Objective] To explore clinical efficacy and safety of selegiline for the treatment of sleep disor‐der in early Parkinson disease(PD) .[Methods] Totally 90 patients with early PD treated by trihexyphenidyl , amantadine and vitamin E were randomly divided into selegiline group and estazolam group .On the basis of the unchanged dose of original drugs ,the former was additionally given selegiline tablet 5mg/d ,while the latter was additionally given estazolam 1mg/d .The course was 4 weeks .All patients were surveyed by Pittsburg sleep quality index(PSQI) questionnaire .The sleep condition before and after treatment was analyzed .Mean‐while ,routine laboratory indexes were detected before and after the addition of the drugs .The incidence of ad‐verse reaction was analyzed and compared .[Results] After treatment ,the PSQI score was significantly im‐proved ,and there was significant difference between before and after treatment( P<0 .01) .There was no sig‐nificant difference in PSQI score after treatment between selegiline group and estazolam group( P > 0 .05) . There were significant differences in the scores of 3 factors(sleep quality ,daytime function and hypnotic drug) in PSQI after treatment between two groups( P <0 .05) .The incidence of adverse reaction in selegiline group and estazolam group was 17 .8% and 36 .9% respectively ,and there was significant difference between two groups( P <0 .05) .The incidence of drowsiness and orthostatic hypotension in selegiline group was signifi‐cantly lower than that in estazolam group( P<0 .01) .[Conclusion]Selegiline for the treatment of sleep disor‐der in PD is safe and effective .Selegiline for reducing hypnotic drug and improving sleep quality of PD patients is obviously superior to estazolam ,so it is worthy of clinical promotion .